Literature DB >> 12643125

Insulin resistance and polycystic ovary syndrome.

David A Ehrmann1.   

Abstract

Insulin resistance plays a central role in the pathogenesis of the reproductive as well as metabolic aberrations that characterize the syndrome. Many women with polycystic ovary syndrome (PCOS) manifest a phenotype that overlaps substantially with the so-called "metabolic syndrome" or "syndrome X." These manifestations include obesity, glucose intolerance, hypertension, macrovascular disease, and dyslipidemia. The etiology and manifestations of insulin resistance in PCOS are reviewed in this article.

Entities:  

Mesh:

Year:  2002        PMID: 12643125     DOI: 10.1007/s11892-002-0061-y

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  52 in total

1.  Altered composition of high density lipoproteins in women with the polycystic ovary syndrome.

Authors:  M Rajkhowa; R H Neary; P Kumpatla; F L Game; P W Jones; M S Obhrai; R N Clayton
Journal:  J Clin Endocrinol Metab       Date:  1997-10       Impact factor: 5.958

Review 2.  Cellular and molecular mechanisms of non-insulin dependent diabetes mellitus.

Authors:  Y T Kruszynska; J M Olefsky
Journal:  J Investig Med       Date:  1996-10       Impact factor: 2.895

Review 3.  Polycystic ovary syndrome: a changing perspective.

Authors:  S Franks
Journal:  Clin Endocrinol (Oxf)       Date:  1989-07       Impact factor: 3.478

Review 4.  Diabetes mellitus. Report of a WHO Study Group.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1985

Review 5.  Vascular thrombosis in type II diabetes mellitus.

Authors:  J A Colwell
Journal:  Diabetes       Date:  1993-01       Impact factor: 9.461

6.  Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance.

Authors:  S Zimmermann; R A Phillips; A Dunaif; D T Finegood; C Wilkenfeld; M Ardeljan; R Gorlin; L R Krakoff
Journal:  J Clin Endocrinol Metab       Date:  1992-08       Impact factor: 5.958

Review 7.  Vascular reactivity.

Authors:  A D Baron
Journal:  Am J Cardiol       Date:  1999-07-08       Impact factor: 2.778

8.  Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome.

Authors:  R A Wild; P C Painter; P B Coulson; K B Carruth; G B Ranney
Journal:  J Clin Endocrinol Metab       Date:  1985-11       Impact factor: 5.958

9.  Defects in beta-cell function in functional ovarian hyperandrogenism.

Authors:  N M O'Meara; J D Blackman; D A Ehrmann; R B Barnes; J B Jaspan; R L Rosenfield; K S Polonsky
Journal:  J Clin Endocrinol Metab       Date:  1993-05       Impact factor: 5.958

10.  Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones.

Authors:  E Dahlgren; S Johansson; G Lindstedt; F Knutsson; A Odén; P O Janson; L A Mattson; N Crona; P A Lundberg
Journal:  Fertil Steril       Date:  1992-03       Impact factor: 7.329

View more
  3 in total

1.  Developmental programming: impact of excess prenatal testosterone on intrauterine fetal endocrine milieu and growth in sheep.

Authors:  Almudena Veiga-Lopez; Teresa L Steckler; David H Abbott; Kathleen B Welch; Puliyur S MohanKumar; David J Phillips; Kent Refsal; Vasantha Padmanabhan
Journal:  Biol Reprod       Date:  2010-08-25       Impact factor: 4.285

2.  A study of ghrelin and leptin levels and their relationship to metabolic profiles in obese and lean Saudi women with polycystic ovary syndrome (PCOS).

Authors:  Maha H Daghestani; Mazin Daghestani; Mamoon Daghistani; Akmal El-Mazny; Geir Bjørklund; Salvatore Chirumbolo; Samar H Al Saggaf; Arjumand Warsy
Journal:  Lipids Health Dis       Date:  2018-08-21       Impact factor: 3.876

3.  Dynamic Change in Insulin Resistance Induced by Free Fatty Acids Is Unchanged Though Insulin Sensitivity Improves Following Endurance Exercise in PCOS.

Authors:  Myint Myint Aye; Alexandra E Butler; Eric S Kilpatrick; Richard Kirk; Rebecca Vince; Alan S Rigby; Derek Sandeman; Stephen L Atkin
Journal:  Front Endocrinol (Lausanne)       Date:  2018-10-05       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.